MétaCan
Menu
Back to cohort
Record W4397006918 · doi:10.1016/j.esmoop.2024.103243

221P Incidence and survival after brain metastases among patients with stage I-III breast cancer: A population-based study

2024· article· en· W4397006918 on OpenAlexaffabout
Rania Chehade, H Soliman, Isabel Fernandes, B. Zhang, Refik Saskin, M.K. Krzyzanowska, G. Liu, Sunit Das, Arjun Sahgal, K.K. Chan, Katarzyna J. Jerzak

Bibliographic record

VenueESMO Open · 2024
Typearticle
Languageen
FieldMedicine
TopicBrain Metastases and Treatment
Canadian institutionsSt. Michael's HospitalPrincess Margaret Cancer CentreUniversity of TorontoUniversity Health NetworkHealth Sciences CentreInstitute for Clinical Evaluative SciencesSunnybrook Health Science Centre
FundersInstituto de Salud Carlos IIISeagenPfizer
KeywordsStage (stratigraphy)Breast cancerIncidence (geometry)OncologyMedicineInternal medicineCancerPopulationBiologyEnvironmental health

Abstract

fetched live from OpenAlex

Patients with HER2-positive (HER2+) and triple-negative (TNBC) metastatic breast cancer (BC) have a high propensity to develop brain metastases (BrM), but BrM incidence among patients who present with early-stage BC has not been well studied. In this population-based cohort study, we used linked administrative databases in Ontario, Canada to identify adult patients diagnosed with stage I-III BC between 2009-2021. Cumulative incidence of surgery and/or radiotherapy for BrM (surrogate for BrM) accounting for competing risk of death, time from primary BC diagnosis to local BrM therapy, and survival time from BrM diagnosis date as stratified by stage and subtype were analyzed using SAS. Of 91, 517 BC patients, 1, 858 (2%) received local treatment for BrM. Median [IQR] age at BrM diagnosis was 52.5 [45-62] years and initial stage at BC presentation was as follows: stage I (n=272; 15%), stage II (n=767, 41%), and stage III (n=819, 44%). With a median follow-up of 6.4 years [IQR:3.7-9.6], the incidence proportion of BrM was: 0.6% among patients with stage I; 2.4% with stage II; and 6.9% with stage III BC. Subtypes included 406 (22%) hormone-receptor-positive (HR+)/HER2-negative (HER2-), 161 (9%) HER2+/HR+, 126 (7%) HER2+/HR-, 288 (15%) TNBC; unknown subtype, n=877 (47%). Among stage III patients, the incidence proportion of BrM was 16% (TNBC), 13% (HER2+/HR-), 9% (HER2+/HR+), and 4% (HR+/HER2-); corresponding median time from initial BC diagnosis to local BrM therapy was 1.6, 2.0, 2.9, and 3.7 years, respectively. Among patients with stage I-III BC treated locally for BrM, median (m) OS from date of BrM treatment was 5.8 (2-16) months. Survival by BC subtype was as follows, irrespective of initial stage at diagnosis: HER2+ BC, mOS=13.1 (4.6-28) months; HR+/HER2- BC, mOS=5.1 (1.7-15) months; TNBC, mOS=3.6 (1.5-8.7) months. A high incidence of BrM among patients with stage III BC was identified particularly among those with TNBC or HER2+ BC. The true incidence is likely higher as screening for asymptomatic BrM is not typically performed. In addition, mOS may be over-estimated because untreated patients were not included in this analysis.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.029
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.305
Teacher spread0.292 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes2
Has abstractyes

Explore more

Same venueESMO OpenSame topicBrain Metastases and TreatmentFrench-language works237,207